RS54840B1 - 1-(3,3-dimetilbutil)-3-(2-fluoro-4-metil-5-(7-metil-2-(metilamino)pirido(2,3-d)pirimidin-6-il)fenil)urea kao inhibitor raf kinaze za tretman kancera - Google Patents
1-(3,3-dimetilbutil)-3-(2-fluoro-4-metil-5-(7-metil-2-(metilamino)pirido(2,3-d)pirimidin-6-il)fenil)urea kao inhibitor raf kinaze za tretman kanceraInfo
- Publication number
- RS54840B1 RS54840B1 RS20160416A RSP20160416A RS54840B1 RS 54840 B1 RS54840 B1 RS 54840B1 RS 20160416 A RS20160416 A RS 20160416A RS P20160416 A RSP20160416 A RS P20160416A RS 54840 B1 RS54840 B1 RS 54840B1
- Authority
- RS
- Serbia
- Prior art keywords
- raf
- methyl
- cancer
- compound
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607702P | 2012-03-07 | 2012-03-07 | |
| EP13712005.1A EP2850082B1 (en) | 2012-03-07 | 2013-03-05 | 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido(2,3-d)pyrimidin-6-yl)phenyl)urea as Raf kinase inhibitor for the treatment of cancer |
| PCT/US2013/029084 WO2013134243A1 (en) | 2012-03-07 | 2013-03-05 | 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS54840B1 true RS54840B1 (sr) | 2016-10-31 |
Family
ID=47884613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20160416A RS54840B1 (sr) | 2012-03-07 | 2013-03-05 | 1-(3,3-dimetilbutil)-3-(2-fluoro-4-metil-5-(7-metil-2-(metilamino)pirido(2,3-d)pirimidin-6-il)fenil)urea kao inhibitor raf kinaze za tretman kancera |
Country Status (39)
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR090151A1 (es) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| AU2017279046B2 (en) * | 2016-06-10 | 2020-07-02 | Novartis Ag | Therapeutic uses of a c-Raf inhibitor |
| JP7219218B2 (ja) | 2016-12-22 | 2023-02-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体 |
| US10787443B2 (en) * | 2017-04-28 | 2020-09-29 | Zamboni Chem Solutions Inc. | RAF-degrading conjugate compounds |
| RS64167B1 (sr) | 2017-12-21 | 2023-05-31 | Boehringer Ingelheim Int | Benzilamino supstituisani piridopirimidinoni i derivati kao sos1 inhibitori |
| JP7161849B2 (ja) * | 2018-01-24 | 2022-10-27 | 株式会社クラレ | 第一級アミンの製造方法 |
| KR102708177B1 (ko) | 2018-01-31 | 2024-09-23 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양의 치료를 위한 병용 요법 |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| SMT202500389T1 (it) | 2018-12-28 | 2025-11-10 | Deciphera Pharmaceuticals Llc | Inibitori di csf1r per l'uso nel trattamento di tumori tenosinoviali a cellule giganti |
| HUE064734T2 (hu) | 2019-02-06 | 2024-04-28 | Lilly Co Eli | 1-((2-(2,2,2-trifluoretoxi)piridin-4-il)metil)karbamid származékok mint KCNQ potenciátorok |
| CN113795307A (zh) * | 2019-02-18 | 2021-12-14 | 基因泰克公司 | 吡啶并嘧啶基化合物及其使用方法 |
| EP3938363A1 (en) | 2019-03-11 | 2022-01-19 | Teva Pharmaceuticals International GmbH | Solid state forms of ripretinib |
| US10927111B2 (en) | 2019-05-03 | 2021-02-23 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| MX2021013662A (es) | 2019-05-10 | 2022-03-11 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos. |
| EP3966207B1 (en) | 2019-05-10 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| IL325201A (en) | 2019-06-17 | 2026-02-01 | Deciphera Pharmaceuticals Llc | Aminopyrimidine amide autophagy inhibitors and methods of using them |
| LT4013412T (lt) | 2019-08-12 | 2026-03-25 | Deciphera Pharmaceuticals, Llc | Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui |
| PT4013412T (pt) | 2019-08-12 | 2026-03-18 | Deciphera Pharmaceuticals Llc | Ripretinib para o tratamento de tumores estromais gastrointestinais |
| BR112022007612A2 (pt) | 2019-10-24 | 2022-09-20 | Kinnate Biopharma Inc | Inibidores de raf quinases |
| CN115243681B (zh) | 2019-12-30 | 2024-08-16 | 德西费拉制药有限责任公司 | 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物 |
| HRP20231699T1 (hr) | 2019-12-30 | 2024-05-10 | Deciphera Pharmaceuticals, Llc | Formulacije inhibitora amorfne kinaze i postupci njihove primjene |
| WO2021245055A1 (en) | 2020-06-02 | 2021-12-09 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| US11407737B2 (en) | 2020-09-18 | 2022-08-09 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| JP7805363B2 (ja) | 2020-11-02 | 2026-01-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＥＧＦＲ阻害薬としての置換１Ｈ－ピラゾロ［４，３－ｃ］及び誘導体 |
| MX2023005747A (es) | 2020-11-18 | 2023-07-28 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos. |
| US20240051956A1 (en) | 2020-12-22 | 2024-02-15 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| CN117561057A (zh) | 2021-04-23 | 2024-02-13 | 金耐特生物制药公司 | 用raf抑制剂治疗癌症 |
| US12065427B2 (en) | 2021-04-29 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating STING |
| US20250129096A1 (en) | 2021-12-01 | 2025-04-24 | Boehringer Ingelheim Int'l GmbH Corp. | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| US20250313553A1 (en) | 2021-12-01 | 2025-10-09 | Boehringer Ingelheim Int'l GmbH Corp. | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2023099624A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| US20250145608A1 (en) | 2021-12-01 | 2025-05-08 | Boehringer Ingelheim Int'l GmbH Corp. | Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes |
| JP2024543982A (ja) | 2021-12-01 | 2024-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | がんの処置のための縮環２－アミノ－３－シアノチオフェン及び誘導体 |
| CN118647620A (zh) | 2021-12-01 | 2024-09-13 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物 |
| KR20240113496A (ko) | 2021-12-03 | 2024-07-22 | 데시페라 파마슈티칼스, 엘엘씨. | Gcn2 및 perk 키나아제 억제제로서의 헤테로고리 화합물 |
| US12319655B2 (en) | 2021-12-09 | 2025-06-03 | Deciphera Pharmaceuticals, Llc | RAF kinase inhibitors and methods of use thereof |
| CA3240192A1 (en) | 2021-12-09 | 2023-06-15 | Daniel L. Flynn | Raf kinase inhibitors and methods of use thereof |
| EP4452975A1 (en) | 2021-12-23 | 2024-10-30 | Boehringer Ingelheim International GmbH | 8-aza quinazolines as brain-penetrant sos1-inhibitors |
| WO2023173017A1 (en) * | 2022-03-09 | 2023-09-14 | Blossomhill Therapeutics, Inc. | Kras inhibitors for treating disease |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| TW202432545A (zh) | 2022-10-26 | 2024-08-16 | 德商百靈佳殷格翰國際股份有限公司 | 可活化sting之雜環化合物 |
| CA3267008A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING |
| TW202432114A (zh) | 2022-10-26 | 2024-08-16 | 德商百靈佳殷格翰國際股份有限公司 | 可活化sting之雜環化合物 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| EP4719603A1 (en) | 2023-05-30 | 2026-04-08 | Boehringer Ingelheim International GmbH | Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| GB2631397A (en) | 2023-06-28 | 2025-01-08 | Sevenless Therapeutics Ltd | New treatments for pain |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| GB2633813A (en) | 2023-09-21 | 2025-03-26 | Sevenless Therapeutics Ltd | New treatments for pain |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025083426A1 (en) | 2023-10-20 | 2025-04-24 | Sevenless Therapeutics Limited | New treatments for pain |
| US20250206720A1 (en) | 2023-12-08 | 2025-06-26 | Deciphera Pharmaceuticals, Llc | Solid forms of an ulk inhibitor |
| WO2025122952A1 (en) | 2023-12-08 | 2025-06-12 | Deciphera Pharmaceuticals, Llc | Formulations of vimseltinib |
| TW202542151A (zh) | 2023-12-22 | 2025-11-01 | 美商銳格醫藥有限公司 | Ｓｏｓ１抑制劑及其用途 |
| WO2025146548A1 (en) | 2024-01-04 | 2025-07-10 | Sevenless Therapeutics Limited | Sos1 inhibitors useful to treat pain and cancer |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202602876A (zh) | 2024-04-03 | 2026-01-16 | 德商百靈佳殷格翰國際股份有限公司 | 作為ｓｏｓ１抑制劑的新穎雙環芐基醯胺吡啶衍生物 |
| WO2025231106A1 (en) | 2024-05-01 | 2025-11-06 | Deciphera Pharmaceuticals, Llc | Csf-1r inhibitors and methods of use thereof |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1447405A4 (en) * | 2001-10-17 | 2005-01-12 | Kirin Brewery | CHINOLIN OR CHINAZOLINE DERIVATIVES THAT PREVENT THE AUTOPHOSPHORYLATION OF RECEPTORS FOR THE FIBROBLAST GROWTH FACTOR |
| AU2003280599A1 (en) * | 2002-10-29 | 2004-05-25 | Kirin Beer Kabushiki Kaisha | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| UY33221A (es) * | 2010-02-09 | 2011-09-30 | Univ California | MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA |
| AR090151A1 (es) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
-
2013
- 2013-02-26 AR ARP130100576A patent/AR090151A1/es unknown
- 2013-02-27 TW TW102107122A patent/TW201348233A/zh unknown
- 2013-03-05 HK HK15103082.6A patent/HK1202541A1/xx unknown
- 2013-03-05 WO PCT/US2013/029084 patent/WO2013134243A1/en not_active Ceased
- 2013-03-05 RS RS20160416A patent/RS54840B1/sr unknown
- 2013-03-05 SI SI201330188A patent/SI2850082T1/sl unknown
- 2013-03-05 IN IN1575MUN2014 patent/IN2014MN01575A/en unknown
- 2013-03-05 MX MX2014010701A patent/MX2014010701A/es unknown
- 2013-03-05 JP JP2014561029A patent/JP2015509536A/ja not_active Ceased
- 2013-03-05 US US13/785,575 patent/US8741911B2/en not_active Expired - Fee Related
- 2013-03-05 EP EP13712005.1A patent/EP2850082B1/en active Active
- 2013-03-05 US US14/383,799 patent/US9334267B2/en not_active Expired - Fee Related
- 2013-03-05 AU AU2013230146A patent/AU2013230146B2/en not_active Ceased
- 2013-03-05 DK DK13712005.1T patent/DK2850082T3/en active
- 2013-03-05 SG SG11201404969YA patent/SG11201404969YA/en unknown
- 2013-03-05 HR HRP20160654TT patent/HRP20160654T1/hr unknown
- 2013-03-05 CA CA2863673A patent/CA2863673A1/en not_active Abandoned
- 2013-03-05 PE PE2014001381A patent/PE20142338A1/es not_active Application Discontinuation
- 2013-03-05 ME MEP-2016-124A patent/ME02423B/me unknown
- 2013-03-05 AP AP2014007899A patent/AP2014007899A0/xx unknown
- 2013-03-05 ES ES13712005.1T patent/ES2584387T3/es active Active
- 2013-03-05 LT LTEP13712005.1T patent/LT2850082T/lt unknown
- 2013-03-05 NZ NZ627454A patent/NZ627454A/en not_active IP Right Cessation
- 2013-03-05 BR BR112014018528A patent/BR112014018528A8/pt not_active IP Right Cessation
- 2013-03-05 WO PCT/US2013/029098 patent/WO2013134252A1/en not_active Ceased
- 2013-03-05 CN CN201380012913.9A patent/CN104302646B/zh not_active Expired - Fee Related
- 2013-03-05 PT PT137120051T patent/PT2850082T/pt unknown
- 2013-03-05 HU HUE13712005A patent/HUE028095T2/en unknown
- 2013-03-05 MA MA37316A patent/MA37316B1/fr unknown
- 2013-03-05 EA EA201491456A patent/EA024824B1/ru not_active IP Right Cessation
- 2013-03-05 KR KR1020147024732A patent/KR20140129087A/ko not_active Abandoned
- 2013-05-03 UA UAA201409109A patent/UA112340C2/uk unknown
-
2014
- 2014-07-24 CO CO14161404A patent/CO7010837A2/es unknown
- 2014-08-11 IL IL234052A patent/IL234052A/en not_active IP Right Cessation
- 2014-08-12 CR CR20140378A patent/CR20140378A/es unknown
- 2014-08-21 CL CL2014002220A patent/CL2014002220A1/es unknown
- 2014-09-03 TN TNP2014000375A patent/TN2014000375A1/fr unknown
- 2014-09-04 DO DO2014000200A patent/DOP2014000200A/es unknown
- 2014-09-05 EC ECIEPI201417584A patent/ECSP14017584A/es unknown
- 2014-09-05 PH PH12014501986A patent/PH12014501986A1/en unknown
-
2016
- 2016-07-22 CY CY20161100719T patent/CY1117846T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS54840B1 (sr) | 1-(3,3-dimetilbutil)-3-(2-fluoro-4-metil-5-(7-metil-2-(metilamino)pirido(2,3-d)pirimidin-6-il)fenil)urea kao inhibitor raf kinaze za tretman kancera | |
| JP4870150B2 (ja) | タンパク質キナーゼ阻害剤として適するフェニルアセトアミド | |
| US9187474B2 (en) | Raf inhibitor compounds | |
| JP2022017384A (ja) | 新規ｕｌｋ１阻害剤およびそれを使用する方法 | |
| CN102574842B (zh) | 用于抑制pi3激酶的吡啶基咪唑酮衍生物 | |
| KR20210098960A (ko) | Helios의 소분자 분해제 및 사용 방법 | |
| KR20200028966A (ko) | Efgr 티로신 키나제의 임상적으로 중요한 돌연변이체의 선택적 억제제 | |
| JP2016507509A (ja) | タンパク質キナーゼの阻害薬としてのアザインドール誘導体 | |
| CN101528702A (zh) | 喹啉化合物和使用方法 | |
| KR20090064602A (ko) | 단백질 키나제 억제제로서 유용한 페닐아세트아미드 | |
| CN104321322A (zh) | 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物 | |
| CN115768757B (zh) | Cd206调节剂及其用途和制备方法 | |
| CN105492445B (zh) | 化合物(变体)以及其对于治疗肿瘤疾病的应用 | |
| TW201900648A (zh) | 治療性化合物及組成物以及其使用方法 | |
| CN116568671A (zh) | 杂环Cullin-RING泛素连接酶化合物及其用途 | |
| US20240376076A1 (en) | Inhibitors targeting ubiquitin specific protease 7 (usp7) | |
| WO2023036252A1 (zh) | 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途 | |
| TWI546304B (zh) | Protein tyrosine kinase inhibitors and their use | |
| KR102783635B1 (ko) | 피리도[3,2-d]피리미딘 화합물, 증식성 질환을 치료하기 위한 이의 용도 | |
| WO2026061424A1 (zh) | 一种化合物、包含其的药物组合物及其用途 | |
| CN120035595A (zh) | 噻唑并[5,4-d]嘧啶化合物、包含其的组合物及其用途 | |
| WO2023082044A1 (zh) | 5-醛基杂环酰胺类化合物及其应用 | |
| HK40029259A (en) | Pyrazolopyrimidine compounds as jak inhibitors |